HIF-1α modulation by topoisomerase inhibitors in A549, a non-small cell lung cancer cell line Source: Annual Congress 2007 - Biology in thoracic oncology Year: 2007
The influence of conventional and targeted chemotherapy on the expression of stem cell markers in lung cancer cell lines Source: International Congress 2017 – Lung cancer: latest basic research on molecular alterations, tumour-immune system-microenvironment interplay and the metabolome Year: 2017
Deguelin enhances chemosensitivity of non-small cell lung cancer cells Source: Eur Respir J 2006; 28: Suppl. 50, 336s Year: 2006
Adaptation to hypoxia leads to apoptosis resistance to cisplatin in non-small cell lung cancer (NSCLC) cell line Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008
Expression of RASGRF2 in non-small cell lung cancer and its effect of transfection on biological behavior of human NSCLC lines H1299 Source: Annual Congress 2012 - New aspects of lung cancer biology Year: 2012
Endoscopical laser treatment in combined therapy non small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002
The effects of TNF-α combined with VP16 on growth and cell cycle of lung cancer cell line and the adhesive molecules Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009
Functional consequences of cathepsin L-deficiency in the human lung carcinoma cell line A549 Source: Eur Respir J 2001; 18: Suppl. 33, 75s Year: 2001
Ghrelin does not influence cancer progression in a lung cancer cell line and mice with lung adenocarcinoma Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018
The influence of brown adipose tissue on the proliferation and chemosensitivity in non-small cell lung cancer cells Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018
New treatment options for nonsmall cell lung cancer and small cell lung cancer Source: Annual Congress 2006 - PG12 - Small cell lung cancer management Year: 2006
New chemotherapeutic agents Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=259 Year: 2001
Relationship between mutated P53 and the acquired multi-drug resistance after cisplatin selection in NCI-H460 cell line of human large cell lung cancer Source: Annual Congress 2004 - Molecular biology Year: 2004
Survival of patients with relapsing small cell lung cancer (SCLC) after new line chemotherapy administration Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005
IRP2 as a potential modulator of cell proliferation, apoptosis and prognosis in nonsmall cell lung cancer Source: Eur Respir J , 49 (4) 1600711; DOI: 10.1183/13993003.00711-2016 Year: 2017
The effects of dalteparin, a kind of low molecular weight heparin, on lung adenocarcinoma A549 cell line in vitro Source: Annual Congress 2008 - Biology and diagnosis of thoracic tumours Year: 2008
Does the incorporation of new generation cytotoxic agent improve the overall outcome in inoperable nonsmall cell lung cancer (NSCLC)? Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003
Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment Source: Eur Respir J 2002; 20: Suppl. 38, 400s Year: 2002